22nd week of 2012 patent applcation highlights part 34 |
Patent application number | Title | Published |
20120135018 | ERG MONOCLONAL ANTIBODIES - Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG anti-body. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting. The antibodies can also be used to inhibit the activity of ERG or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript and to treat malignancies associated with overexpression of ERG or an ERG fusion event, such as prostate cancer, Ewing's sarcoma, acute myeloid leukemia, acute T-lymphoblastic leukemia, endothelial cancer, and colon cancer. | 2012-05-31 |
20120135019 | FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS - The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4 | 2012-05-31 |
20120135020 | TTK PEPTIDES AND VACCINES INCLUDING THE SAME - Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention. | 2012-05-31 |
20120135021 | CELL PENETRATING PEPTIDES AND ITS USE FUSED TO BIOMOLECULES WITH THERAPEUTIC ACTION - The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein | 2012-05-31 |
20120135022 | ASSEMBLY ACTIVATING PROTEIN (AAP) AND ITS USE FOR THE MANUFACTURE OF PARVOVIRUS PARTICLES ESSENTIALLY CONSISTING OF VP3 - The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The present invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use. | 2012-05-31 |
20120135023 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2012-05-31 |
20120135024 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 2012-05-31 |
20120135025 | CHLAMYDIA ANTIGENS AND USES THEREOF - The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., T cell-mediated and/or B cell-mediated immune responses). The present invention provides methods of prophylaxis and/or treatment of chlamydia-mediated diseases comprising administering an immunogenic composition including one or more of the novel antigens described herein. | 2012-05-31 |
20120135026 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 2012-05-31 |
20120135027 | PROTEINS USED FOR THE DIAGNOSIS OF LYME BORRELIOSIS - Chimera proteins including: (i) at least one sequence of a DbpA protein of a | 2012-05-31 |
20120135028 | VACCINE - The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided. | 2012-05-31 |
20120135029 | METHOD FOR THE PURIFICATION OF PROTEIN COMPLEXES - The present invention provides an improved method for the purification of a mixture of complexes comprising a stress protein complexed to a peptide or peptide fragment from a source mixture, typically a cell lysate. The method of the invention provides for protein complexes to be purified using ion exchange chromatography based methods, wherein a modified buffer solution is used which results in the purified stress protein complexes being more immunogenic than protein complexes obtained using conventional methodology. The purified complexes can be used to produce improved vaccine preparations which elicit enhanced immune responses in the subjects to whom the vaccine compositions are administered. | 2012-05-31 |
20120135030 | Method of Producing Protein-Carbohydrate Vaccines Reduced in Free Carbohydrate - This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate. | 2012-05-31 |
20120135031 | METHOD OF ENHANCING AN IMMUNE RESPONSE - A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/or TAP-2 molecule. The method is useful in treating infectious diseases and cancer. | 2012-05-31 |
20120135032 | GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIV - The present invention relates to a recombinant Modified Vaccinia virus Ankara (MVA) comprising in the viral genome one or more expression cassettes for the expression of HIV proteins selected from Gag, Pol, Tat, Vif, Vpu, Vpr, Rev and Nef or a part or a derivative thereof or selected from Gag, Pol, Vpu, Vpr, Rev and Nef or a part or a derivative thereof for use as medicament or vaccine and its use for the treatment and/or prevention of HIV infections and AIDS. | 2012-05-31 |
20120135033 | MULTIPLE DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - The invention is directed to an episomal recombinant nucleic acid encoding at least two heterologous antigens each fused to a PEST-endogenous polypeptide, vaccines comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering the same. | 2012-05-31 |
20120135034 | Non-Integrating Retroviral Vector Vaccines - This invention relates to non-integrating, non-replicating retroviral vectors that cause an immune response in an animal host when administered to the host. The vectors transduce cells in the host, where they produce virus-like particles (VLPs), which stimulate an additional immune response in the host when they are released from the cells. The vectors are non-integrating, non-replicating retroviral vectors comprising long terminal repeats, a packaging sequence, and a heterologous promoter operably linked to one or more polynucleotide sequences that together encode the structural proteins of a virus. Methods of making and using the vectors are also disclosed. | 2012-05-31 |
20120135035 | Induction of an immune response against dengue virus using the prime-boost approach - The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins. | 2012-05-31 |
20120135036 | BACTERIAL COMPOSITION AND ITS USE - The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of | 2012-05-31 |
20120135037 | FLAGELLIN FUSION PROTEINS AND CONJUGATES COMPRISING PNEUMOCOCCUS ANTIGENS AND METHODS OF USING THE SAME - The present invention is based, in part, on flagellin adjuvant used to enhance immune responses directed against | 2012-05-31 |
20120135038 | EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against | 2012-05-31 |
20120135039 | Oral Vaccines for Producing Mucosal Immunity - Embodiments of this invention include lipid-based immunogenic compositions (adjuvants or carriers) useful for oral or gastrointestinal administration for improving mucosal immune responses in animals vaccinated for a variety of bacterial infections. In certain embodiments, lipid compositions of this invention include a mixture of fatty acids having different chain lengths, thereby providing desired physico-chemical properties. When a bacterial antigen is mixed with a lipid-based adjuvant or carrier, the resulting composition elicits improved mucosal immune responses and thereby decreases infections and sequellae of disease caused by | 2012-05-31 |
20120135040 | TEMPERATURE SENSITIVE VACCINE STRAIN OF MYCOPLASMA HYOPNEUMONIAE AND USES THEREOF - The present invention relates to a | 2012-05-31 |
20120135041 | IMMUNOSUPPRESSOR BASED ON THE BLOCKAGE OF TCR-NCK INTERACTION - The present invention relates to a compound of structural formula (I) and its derivatives for use as medicinal drugs. They are preferably immunosuppressive agents, with mechanism of action based on the blockage of TCR-Nck interaction. | 2012-05-31 |
20120135042 | Methods Using Immunomodulatory Compounds For Treatment of Certain Leukemias - Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention. The invention further relates to methods of treatment using an immunomodulatory compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed. | 2012-05-31 |
20120135043 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 2012-05-31 |
20120135044 | INSTANT THICKENER COMPRISING PROBIOTICS FOR HOT OR COLD FOODS AND BEVERAGES TO BE ADMINISTERED TO DYSPHAGIC PATIENTS - The present invention relates to the fields of hydration and nutrition for dysphagic patients. In particular, the present invention relates to thickeners comprising probiotic microorganisms and to compositions comprising such thickeners. The probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic microorganisms. | 2012-05-31 |
20120135045 | Antimicrobial Collagenous Constructs - Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with an antimicrobial agent. The constructs are biocompatible. The present invention has a variety of applications, including wound dressing and surgical repair devices. Methods for treating a damaged or diseased soft tissue are provided. Methods for treating a wound in need of care and treatment are also disclosed. | 2012-05-31 |
20120135046 | CORTICOSTEROID PARTICLES AND METHOD OF PRODUCTION - A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area. | 2012-05-31 |
20120135047 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 2012-05-31 |
20120135048 | NOVEL FORMULATION OF INDOMETHACIN - The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments. | 2012-05-31 |
20120135049 | Decellularized tissue engineered constructs and tissues - Methods for producing tissue engineered constructs and engineered native tissues include producing a tissue engineered construct by growing cells in vitro on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed. The decellularized construct can be used for further tissue engineering, which may include seeding the construct with cells obtained from the intended recipient of the construct. During any of the growth phases required for production of the construct, the developing construct may be subjected to various tissue engineering steps such as application of mechanical stimuli including pulsatile forces. | 2012-05-31 |
20120135051 | GENERATION OF VASCULARIZED HUMAN HEART TISSUE AND USES THEREOF - The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+/NKX2.5−/KDR−. One aspect of the invention relates to isolation of human ISL1+ primordial cells from human pluripotent cells, such as human ES cells or other human pluripotent stem cell sources, wherein the human ISL1+ primordial cells can differentiate into three different lineages; cardiomyocyte lineages, endothelial lineages and smooth muscle lineages. Another aspect relates to use and implantation of the human primordial ISL1+ progenitors into an animal model to generate human vascularized heart tissue, and more particularly, the production of an in vivo humanized model of vascular disease. One embodiment relates to the use of an in vivo humanized model of vascular disease as an assay, for example to assess drug toxicity and/or identify agents which increase and decrease coronary blood flow to the human vascularized heart tissue. Another embodiment relates to the therapeutic use of human primordial ISL1+ progenitors, for example, in one embodiment the invention provides methods for the treatment cardiovascular disorders and/or congenital heart disease in a subject comprising transplanting into subjects vascularized human heart tissue generated from human ISL1+ progenitors. | 2012-05-31 |
20120135052 | METHOD FOR PREPARING AN ORGANIC-COMPATIBLE AND WATER-COMPATIBLE COMPOSITION OF METAL NANOCRYSTALS, AND RESULTING COMPOSITION - A method for preparing a composition of metal nanocrystals from at least one organometallic precursor in a solvent medium in the presence of a PEG ligand, including a carbon chain, at least one end of which is functionalized by a coordination grouping including at least one hetero atom, and having at least one [OCH | 2012-05-31 |
20120135053 | NANOPARTICULATE TELMISARTAN COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF - The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. | 2012-05-31 |
20120135054 | Poly (Ester Ether Amide)s and Uses Thereof - Cationic poly(ester ether amide)s (PEEAs) and compositions comprising PEEAs and biomolecules such as nucleic acids and proteins. Also, a method for intracellular delivery of biomolecules using complexes of the PEEAs and biomolecules. For example, PEEAs can be used as transfection agents for nucleic acids such as DNA and RNA. | 2012-05-31 |
20120135055 | Dry Powder Inhaler Formulations - A dpi formulation comprises a solvate of beclomethasone and is substantially free of excipient and free of carrier. The solvate particles are of size 0.5 to 10 microns and are obtained by crystallization of the steroid in the presence of ultrasound. | 2012-05-31 |
20120135056 | ANTIPERSPIRANT COMPOSITIONS AND PRODUCTS HAVING PREDETERMINED EFFECTS AND METHODS FOR MAKING THE SAME - A personal care product comprises an antiperspirant product housed within a container. The antiperspirant product comprises a first portion comprising a first ingredient. A second portion is macroscopically separated from the first portion. The second portion has a composition different from the first portion and comprises a second ingredient effective to interact with the first ingredient to produce a predetermined effect. | 2012-05-31 |
20120135057 | ANTIPERSPIRANT COMPOSITIONS AND PRODUCTS HAVING A DISPERSED COOLING SENSATION AGENT AND METHODS FOR MAKING THE SAME - A personal care product comprises an antiperspirant product that is housed within a container. The antiperspirant product comprises a dispersed cooling sensation agent that is adsorbed onto surfaces of silica particles that are dispersed throughout the antiperspirant product, absorbed into pores of the silica particles or a combination thereof. | 2012-05-31 |
20120135058 | NANODISPERSIONS - The invention provides process for making contra-soluble nano-dispersions of at most sparingly-soluble materials in a soluble carrier material comprising the steps of:
| 2012-05-31 |
20120135059 | PREPARATION FOR ORAL CAVITY - Object of the present invention is to provide a preparation for oral cavity that is appropriately usable as a prophylactic agent for dental caries, a therapeutic agent for dental caries at early stage, a prophylactic and/or therapeutic agent for dentinal hypersensitivity, a preparation for the lining of a dentin cavity surface, or the like, which has a superior effect of sealing the dentinal tubules, is capable of improving the acid resistance of the teeth and re-calcifying the teeth, ensures a short-time treatment with an easy operation, and has a high safety and good aesthetic properties. The object is achieved by a preparation for oral cavity such as a prophylactic agent for dental caries and/or a therapeutic agent for dental caries at early stage, a prophylactic and/or therapeutic agent for dentinal hypersensitivity, a preparation for the lining of a dentin cavity surface, or the like, consisting of a liquid (A), in which fluoro-alumino-silicate glass microparticles are dispersed, and an aqueous inorganic phosphoric acid solution (B). | 2012-05-31 |
20120135060 | COMPOSITIONS AND METHODS FOR CELL KILLING - Provided herein are biocidic compositions including an ion exchange material, wherein when said material is in an environment capable of transporting H | 2012-05-31 |
20120135061 | PARY-XYLENE BASED MICROFILM ELUTION DEVICES - This invention is in the field of controlled elution devices for therapeutic delivery. There exists a need for a stand-alone capable device for the localized and extended delivery of a therapeutic. This need is overcome by the present invention having an exemplary embodiment comprised of a microfilm base ( | 2012-05-31 |
20120135062 | WOUND DRESSING MATERIALS - A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials. | 2012-05-31 |
20120135063 | GLUCURONIC ACID-CONTAINING GLUCAN, PROCESS FOR PRODUCTION OF SAME, AND USE OF SAME - An object of the present invention is to provide a uronic acid-containing glucan or a modified product thereof. The glucuronic acid-containing glucan of the present invention is a glucuronic acid-containing glucan in which a glucuronic acid residue is bound to at least one non-reducing end of a glucan, and the glucan is a branched α-1,4 glucan or a linear α-1,4 glucan. The glucuronic acid-containing glucan of the present invention can be provided by allowing α-glucan phosphorylase derived from | 2012-05-31 |
20120135064 | CONJUGATED NANODELIVERY VEHICLES - Anti-angiogenesis agent-linked liposomes and micelles, methods of making such liposomes and micelles, and methods of using such liposomes and micelles, such as for delivery of therapeutic and detection agents to tumor cells, are described. | 2012-05-31 |
20120135065 | Amphoteric Liposomes, A Method Of Formulating An Amphoteric Liposome And A Method Of Loading An Amphoteric Liposome - An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety. | 2012-05-31 |
20120135066 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO - The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations. | 2012-05-31 |
20120135067 | VACCINE FOR MYCOPLASMA INFECTION - Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, | 2012-05-31 |
20120135068 | LIPOSOME-ENCAPSULATED GLUTATHIONE FOR ORAL ADMINISTRATION - The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa. | 2012-05-31 |
20120135069 | NANONIZED TESTOSTERON FORMULATIONS FOR IMPROVED BIOAVAILABILITY - Nanonized formulations of testosterone esters, especially testosterone undecanoate, and of testosterone are prepared which show an enhanced oral bioavailability compared to the existing oral products on the market. The drug is dissolved in a melted lipid phase, which is subsequently nanonized. The drug is associated with the lipid. The drug can also be nanonized without having lipid present yielding nanocrystals. The nanonized drug can be incorporated into tablets or capsules for oral administration, typically one unit is sufficient for delivery of a single dose. | 2012-05-31 |
20120135070 | Copolymers - The invention provides a block copolypeptide comprising a hydrophilic heteropolypeptide block (A) and a hydrophobic homopolypeptide block (B). There is also provided a polymersome comprising a block copolypeptide of the invention. The invention further provides a method for preparing a copolymer comprising ring-opening polymerisation (ROP) of an amino acid N-carboxyanhydride (NCA) initiated from a peptide. | 2012-05-31 |
20120135071 | Abuse-proofed dosage form - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 2012-05-31 |
20120135072 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2012-05-31 |
20120135073 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2012-05-31 |
20120135074 | High-Strength Testosterone Undecanoate Compositions - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the present invention provides for a pharmaceutical composition that includes a therapeutically effective amount of testosterone undecanoate and a solubilizer. The testosterone undecanoate is solubilized in the composition and is present in an amount such that it comprises about 14 wt % to about 35 wt % of the total composition. | 2012-05-31 |
20120135075 | DOSAGE FORM - The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded particulates are present as a discontinuous phase in said matrix. | 2012-05-31 |
20120135076 | INTRABUCCALLY RAPIDLY DISINTEGRATING TABLET AND A PRODUCTION METHOD OF THE TABLETS - An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 μm, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape. | 2012-05-31 |
20120135078 | ANGINA TREATMENT - A xanthine oxidase inhibitor for use in the treatment of angina is described. The angina may be stable angina pectoris and the treatment may be to eliminate, reduce or alleviate one or more symptoms of angina pectoris (such as chest pain), or may be prophylactic. The xanthine oxidase inhibitor may be used in combination with one or more additional therapeutic agents, such as anti-anginal agents. Pharmaceutical compositions, medicaments and kits for the treatment of angina are also described. | 2012-05-31 |
20120135079 | Modified Release Tranexamic Acid Formulation - A modified release dosage form for the oral administration of tranexamic acid. | 2012-05-31 |
20120135080 | Core-Shell Magnetic Particles and Related Methods - The invention provides core-shell magnetic particles comprising a magnetic core and a functional shell, methods for making same, methods of separation using same, methods for using same, and devices comprising same. The particles and methods of the invention are useful for targeting and removing substances of interest that may be found in complex mixtures. | 2012-05-31 |
20120135081 | HYDROPHOBINS FOR DISPERSING ACTIVE AGENTS - In the field of drug or nutrient administration novel particles and formulations thereof are provided. Said particles each have a core comprising active agent and at least partial coating comprising proteins, selected from hydrophobins. Preferable hydrophobins belong to class I or class II. Said particles exhibit enhanced characteristics, for example dispersibility or solubility. Here is also disclosed two methods for producing said particles in nanoscale, of which one utilizes precipitating and another wet milling. | 2012-05-31 |
20120135082 | EXTENDED RELEASE COMPOSITIONS COMPRISING AS ACTIVE COMPOUND VENLAFAXINE HYDROCHLORIDE - The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride. | 2012-05-31 |
20120135083 | DRIED PRODUCT AND A PROCESS FOR MANUFACTURING THE PRODUCT - A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance. | 2012-05-31 |
20120135084 | Use of Deuterium Oxide for Treating Viral Diseases of the Eye - The invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of viral diseases of the eye. | 2012-05-31 |
20120135085 | METHOD AND COMPOSITION FOR DISINFECTION AND PURIFICATION - A method and composition for a non-toxic aqueous silicon solution. | 2012-05-31 |
20120135086 | METHOD OF TISSUE REPAIR USING A COMPOSITE MATERIAL - A composite biocompatible hydrogel material includes a porous polymer matrix, the polymer matrix including a plurality of pores and providing a Young's modulus of at least 10 GPa. A calcium comprising salt is disposed in at least some of the pores. The porous polymer matrix can comprise cellulose, including bacterial cellulose. The composite can be used as a bone graft material. A method of tissue repair within the body of animals includes the steps of providing a composite biocompatible hydrogel material including a porous polymer matrix, the polymer matrix including a plurality of pores and providing a Young's modulus of at least 10 GPa, and inserting the hydrogel material into cartilage or bone tissue of an animal, wherein the hydrogel material supports cell colonization in vitro for autologous cell seeding. | 2012-05-31 |
20120135087 | TOPICAL COMPOSITIONS DESIGNED TO MAINTAIN OR RESTORE THE INTEGRITY OF THE MUCOUS MEMBRANES - The present invention relates to topical compositions containing choline alfoscerate for use in maintaining and restoring the integrity of the mucous membranes. | 2012-05-31 |
20120135088 | FUNGICIDAL COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASES - A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the following formula or its salt: | 2012-05-31 |
20120135089 | E3 LIGASE INHIBITORS - The present invention provides, e.g., compounds having the structure of formula (I): The present invention also provides pharmaceutical compositions that include such compounds, and methods for modulating murine double minute 2 protein (Mdm2) E3 ligase activity, particularly the Mdm2-MdmX hetero-complex E3 ligase activity, using such compounds. | 2012-05-31 |
20120135090 | SOLUTIONS COMPRISING POLYETHYLENE GLYCOL AND ELECTROLYTES - The invention provides a solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N×an amount of flavouring; and (g) optionally N×an amount of sweetener where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions. | 2012-05-31 |
20120135091 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES - The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and/or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described. | 2012-05-31 |
20120135092 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS - Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. In some embodiments, the compound is a N | 2012-05-31 |
20120135093 | SOAP COMPOSITION FOR TREATING ACNE CONTAINING ABSOLUTE GINSENG ESSENTIAL OIL - The present invention discloses a soap composition containing a ginseng absolute oil, based on the finding that a ginseng extract, particularly a ginseng absolute oil, has a potent effect on the treatment of acne. A soap composition for treating acne according to one embodiment of the present invention was used, and as a result, it could be seen that the soap composition exhibited excellent effects of removing sebum and killing acne bacteria to prevent proliferation of the bacteria and infection with the bacteria, thus exhibiting a potent effect on the treatment of acne. | 2012-05-31 |
20120135094 | OREGANO AND MINT ANTI-INFLAMMATORY COMPOSITIONS AND METHODS - The present invention relates to bioactivity-guided isolation and identification of bioactive compounds from oregano and mint plants, in particular, rosmarinic acid, oleanolic acid and ursolic acid, and use of these compounds or combinations thereof as anti-inflammatory agents for the treatment of conditions related to pain and inflammation and/or as ingredients of dietary supplements. The invention also relates to optimization of the methods for qualitative and quantitative analysis of the bioactive compounds in oregano and mint plants. In particular, this invention introduces an LC/MS (SIM mode) method to achieve co-quantitation of the three organic acids using a unique tandem column system. In addition, the invention also relates to the methods for recovering various water-soluble polyphenols and triterpenes from aromatic plants. | 2012-05-31 |
20120135095 | ELECTRICAL CONNECTOR AND METHOD OF MANUFACTURE - An apparatus and method are disclosed for manufacturing an electrical connector. A mold is presented having a pair of opposing dies that each define a mold pocket. The mold pockets of each die can be joined to form a mold cavity. Plastic can be injection molded into the mold cavity to form an electrical connector housing. | 2012-05-31 |
20120135096 | RESIN MOLDING MACHINE - The compact resin molding machine is capable of efficiently performing a sequence of molding actions from feeding a work and resin to accommodating the molded work. The resin molding machine comprises: a work conveying mechanism including a robot, which has a robot hand for holding the work and which is capable of rotating and linearly moving; a work feeding section for feeding the work; a resin feeding section for feeding the resin; a press section including a molding die set, in which the work is resin-molded; a work accommodating section for accommodating the molded work; and a control section controlling the entire resin molding machine. The work feeding section, the resin feeding section, the press section and the work accommodating section are located to enclose a moving area of the robot of the work conveying mechanism. | 2012-05-31 |
20120135097 | Arrangement and method for the electromechanical drive for molding closing systems and calibration blow mandrel systems in blow molding machines - The invention relates to an arrangement and to a method for the electromechanical drive for mold closing systems and calibration blow mandrel systems in blow molding machines, wherein the arrangement for the drive of an extrusion blow molding machine includes a push mechanism ( | 2012-05-31 |
20120135098 | Extrusion Mixing Screw and Method of Use - An extruder screw segment has opposed end faces disposed at a non-orthogonal angle with respect to a rotation axis of the body. | 2012-05-31 |
20120135099 | METHOD AND APPARATUS FOR RAPID MOLDING OF WIND TURBINE BLADES - A compliant cover is placed over a part being molded in a molding process. The compliant cover is formed from a plurality of longitudinal cells positioned next to one another. At least one communication port is coupled to each longitudinal cell, and a source of fluid media at a preselected temperature is coupled to the communication ports whereby the longitudinal cells may be filled with the fluid media at the preselected temperature. The compliant cover may thus be used to selectively heat and cool the part being molded to decrease the time required by the part to rise to the temperature required to cure the resin in the part and to cool the part so that it can be removed from the mold. | 2012-05-31 |
20120135100 | Compression molding machine - In order to achieve reduction of a space occupied in a plant for manufacturing pharmaceutical tablets or the like, there is provided a compression molding machine that includes a table, an upper punch and a lower punch, a molded product collection mechanism, a molded product reservoir, and a housing for accommodating a connection end of an air convey path connected to the molded product reservoir. In this configuration, there is no need to additionally provide a dust removing device or a lifter outside the machine. | 2012-05-31 |
20120135101 | BLOW-MOLDING DEVICE PROVIDED WITH MEANS FOR ATTACHING, BY SUCTION, A HALF-MOLD TO A BACK WALL OF A CORRESPONDING RECESS OF A MOLD CARRIER - Disclosed is a molding device ( | 2012-05-31 |
20120135102 | MOLDING APPARATUS - Disclosed herein is, amongst other things, a molding apparatus that includes a collet ( | 2012-05-31 |
20120135103 | Staged Infant Feeding Regimen To Promote Healthy Development And Growth - A feeding regimen for an infant which includes (a) feeding to a newborn infant a first composition including a fat or lipid; a protein source, wherein the protein source has from about 72% to about 90% whey and from about 10% to about 28% casein; a prebiotic composition; and at least about 72 IU/100 kcal of vitamin D, and (b) feeding to a later stage infant a second composition which includes a fat or lipid; a protein source, wherein the protein source has from about 50% to about 70% whey and from about 30% to about 50% casein; a prebiotic composition; and no greater than 70 IU/100 kcal of vitamin D. | 2012-05-31 |
20120135104 | Enhanced Absorption of Omega Fatty Acid Oils - A composition for increasing the bioavailability of oils in humans and animals comprising mixing a first emulsifier and a second emulsifier in a ratio ranging from about 1:1 to about 3:1 with a consumable oil wherein the first emulsifier is polyoxyethylene sorbitan monooleate and the second emulsifier is tocopheryl polyethylene glycol succinate. A method for increasing the bioavailability of such a composition is also provided. | 2012-05-31 |
20120135105 | TECHNIQUE OF EATING WITH THE HELP OF BRAIN SIGNALS - The present invention provides a technique of eating with the help of brain signals, said technique comprising of controlling the timing of the signals sent/received by the satiety and hunger centre of brain without the use of any external medications. This results in balanced control of the blood circulation to the vital organs of the body, so that proper functioning of organs is achieved and expression of genes is regulated resulting in prevention of metabolic diseases, obesity, malnutrition, metabolic syndrome, etc. | 2012-05-31 |
20120135106 | Biomass Hydrolysate and Uses and Production Thereof - The present invention includes a palatable, stable composition comprising a biomass hydrolysate emulsion for incorporation, into, or used as, nutritional products, cosmetic products or pharmaceutical products. Preferred sources for biomass are microbial sources, plant sources and animal sources. The present invention also provides methods for making such compositions, specifically, a method for producing a product comprising a nutrient, particularly a long chain polyunsaturated fatty acid, comprising hydrolyzing a biomass comprising the nutrient and emulsifying the hydrolyzed biomass. Such compositions and methods are useful, for example, for increasing intake of nutrients such as omega-3 long chain polyunsaturated fatty acids having 18 or more carbons. | 2012-05-31 |
20120135107 | METHOD FOR PREPARING A LEAVENED, MECHANICALLY DEVELOPED BREAD DOUGH - The present invention relates to a method of preparing a leavened bread dough, said method comprising the following sequence of processing steps:
| 2012-05-31 |
20120135108 | Grain Compositions Containing Pre-Biotic Isomal To-Oligosaccharides And Methods Of Making And Using Same - Methods for the production of substrate, tuber, and grain compositions containing isomalto-oligosaccharides are described. The methods comprise (a) contacting a substrate, tuber or grain containing ungelatinized starch with a maltogenic enzyme and a starch liquefying enzyme to produce maltose; (b) contacting said maltose with a transglucosidic enzyme, wherein said steps (a) and step (b) occur at a temperature less than or at a starch gelatinization temperature; and (c) obtaining a substrate, grain or tuber composition having an enzymatically produced isomalto-oligosaccharide, wherein the oligosaccharide is derived from the grain. The maltogenic enzyme can be either exogenous or endogenous to the grain. The contacting steps can be sequential or concurrent. The present invention also describes flour, oral rehydrating solutions, beer adjuncts, food, feed, beverage additives incorporating the grain compositions made as described. | 2012-05-31 |
20120135109 | FIBER OBTAINED FROM FRUIT OR VEGETABLE BYPRODUCTS - A fiber extracted from a fruit or vegetable byproduct is provided, the extracted fiber having a molecular weight of between about 5000 grams/mol (g/mol) and about 8000 g/mol, or a pectic oligosaccharide having a molecular weight of between about 300 g/mol and 2500 g/mol. The fiber may be extracted using physical methods or a combination of a physical method to break the fruit or vegetable byproduct cell walls and enzymatic hydrolysis. Also, a comestible containing the extracted fiber is provided. A method for producing a soluble fiber is further provided including reducing the particle size of a fruit or vegetable byproduct, subjecting the byproduct particles to a physical process to break cell walls of the particles, adding one or more enzymes, mixing or agitating the particles, and filtering the byproduct particles to provide a retentate and a permeate. The permeate contains the soluble fiber, which is optionally a prebiotic fiber. | 2012-05-31 |
20120135110 | COMPOSITION FOR LOW-SALT FOOD OR BEVERAGE - It is possible to adjust the balance of taste of a low-salt food or beverage and to impart good taste to the low-salt food or beverage for general purposes without the need of imparting a salty taste to the low-salt food or beverage, by adding a hydrolysate of a plant-derived protein and an yeast extract are added to a low-salt food or beverage. | 2012-05-31 |
20120135111 | ENZYME PREPARATION FOR REFORMING PROCESSED MEAT PRODUCTS AND MANUFACTURING METHOD FOR PROCESSED MEAT PRODUCTS - By using phospholipase C and/or phospholipase D when producing a processed meat product, water content released while the processed meat product is stored can be suppressed without adversely affecting the texture, such as the hardness and flexibility, of the processed meat product. | 2012-05-31 |
20120135112 | YEAST, PREPARATION METHOD, COMPOSITION, APPARATUS AND USES THEREOF - The invention relates to a method for preparing yeast, to a yeast obtained according to the method, to a food composition comprising the yeast, to an apparatus intended for implementing the method and to various uses of the yeast in a baker's dough. More specifically, the method consists in dehydrating yeast cream, granulating this yeast, and then drying. | 2012-05-31 |
20120135113 | Edible Energy Composition - An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, preservatives, and the like. | 2012-05-31 |
20120135114 | PACKAGING OF RESPIRING BIOLOGICAL MATERIALS - Packaging of bananas in containers, for example polyethylene bags, having designed permeabilities to oxygen, carbon dioxide, and ethylene. The bags preferably include a gas-permeable membrane comprising (1) a microporous film, and (2) a polymeric coating on the microporous film. The containers enable storage and/or ripening of bananas under controlled conditions. Using the new containers, bananas can be ripened while they are being transported, or in conventional ripening rooms without opening the containers in which they have been transported, or after they have left a ripening room. In addition, bananas can be preserved in a satisfactory ripened state for longer periods of time. | 2012-05-31 |
20120135115 | Method for Preparation of Hard Foods for Consumption - A method for preparation of a hard food for consumption, the method including performance of steps of providing a vessel having an interior space; partially filling the vessel's interior space with water; further filling the vessel's interior space with the hard food; absorbing a portion of the water into the hard food during a soaking time to form a water and food media; providing an ultrasonic transducer and operatively associating the ultrasonic transducer with the vessel's interior space; providing an ultrasound generator and operatively connecting the ultrasound generator with the ultrasonic transducer; and operating the ultrasound generator and the ultrasonic transducer to drive multiplicities of cavitating waves through the water and food media. | 2012-05-31 |
20120135116 | PROCESS FOR PRODUCING A SOY PROTEIN WATER DISPERSION - In this disclosure there are provided processes for providing a Soy Protein Flour water dispersion with reduced viscosity. Also provided in the disclosure are Soy Protein Flour dispersions with reduced viscosity, and the use of Soy Protein Flour dispersions with reduced viscosity. | 2012-05-31 |
20120135117 | PRODUCTION OF SOLUBLE PROTEIN SOLUTIONS FROM PULSES - A pulse protein product, which may be an isolate, produces heat-stable solutions at low pH values and is useful for the fortification of acidic beverages such as soft drinks and sports drinks without precipitation of protein. The pulse protein product is obtained by extracting a pulse protein source material with an aqueous calcium salt solution to form an aqueous pulse protein solution, separating the aqueous pulse protein solution from residual pulse protein source, adjusting the pH of the aqueous pulse protein solution to a pH of about 1.5 to about 4.4 to produce an acidified pulse protein solution, which may be dried, following optional concentration and diafiltration, to provide the pulse protein product. | 2012-05-31 |
20120135118 | Method to produce, transport, and utilize flour and flour blends - A method to produce a food product comprises the steps of providing a plurality of flint corn kernels; drying the flint corn kernels; popping the flint corn kernels; cooling the porous, airy, elastic foam particles produced during popping; cutting with a moving blade said porous, airy foam particles into pieces having a width greater than 0.005 inches to produce an elastic, air entrained popcorn flour occupying a volume; and, vacuum packaging the elastic popcorn flour to reduce the volume occupied by the popcorn flour. | 2012-05-31 |
20120135119 | BREWING PROCESS - The invention relates to a method for brewing coffee in a coffee machine, particularly an automatic or fully automated espresso machine, wherein coffee beans are ground to coffee powder of a predefined quantity of coffee powder and/or a predefined grinding degree by a grinding device of the coffee machine, during a press process, the coffee powder is pressed in a brewing chamber of the coffee machine at a predefined press force, during the brewing process, a predefined quantity of water, heated to a predefined brewing temperature is passed through the coffee powder and an actual brewing time is determined, the actual brewing time is compared to a saved target brewing time, the actual brewing time is adapted to the target brewing time by increasing/reducing the press force during the brewing process or before every new coffee brewing. Thus, the brewing time can be controlled by the press force. | 2012-05-31 |